Study on Thyroid Hormone Therapy in Subclinical Hypothyroidism
Understanding Subclinical Hypothyroidism
A recent study published in JAMA investigates the appropriateness of thyroid hormone therapy for patients with subclinical hypothyroidism. This condition marks the early stages of thyroid dysfunction, where the thyroid gland does not produce sufficient hormones. It predominantly affects older adults and women and is linked to symptoms such as weight gain and fatigue. Thyroid hormone replacement therapy is a potential treatment aimed at compensating for the reduced hormone production and normalizing hormone levels.
Lack of Large-Scale Clinical Trials
Despite the existence of subclinical hypothyroidism, there has been a lack of substantial evidence and large-scale clinical trials to guide physicians in their treatment decisions. To address this gap, a research team from Switzerland conducted a systematic review and meta-analysis to consolidate existing evidence and enhance clinical decision-making. Their findings were published in JAMA.
Methodology and Findings
The research team initially identified 3,088 publications related to randomized clinical trials. They filtered these studies based on specific criteria, ultimately analyzing 21 randomized trials that involved 2,192 non-pregnant adults diagnosed with subclinical hypothyroidism. For reliability, the selection process was conducted independently by two reviewers.
No Significant Benefits Observed
The analysis of the 21 studies revealed that thyroid hormone replacement therapy did not yield any significant benefits in patient outcomes. Specifically, the therapy did not enhance the general quality of life or thyroid-related quality of life among participants. Additionally, other measured outcomes, including depressive symptoms, cognitive function, muscle strength, blood pressure, and body mass index, exhibited no significant improvements when compared to placebo controls.
Implications for Treatment Guidelines
This study included the two largest randomized clinical trials published to date, providing new evidence that thyroid hormone replacement therapy is no more effective than no treatment at all. These findings could prompt a reevaluation of treatment guidelines for subclinical hypothyroidism worldwide. The resulting changes may lead to reduced healthcare spending without compromising patient health.
Written by Branson Chen, BHSc
Reference: Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, Ford I, Gussekloo J, Kearney PM, Mooijaart S, Quinn T. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018 Oct 2;320(13):1349-59.